Brief: Valneva Eyes 2026 Total Revenues OF EUR 155-170 Mln
18/03/2026 06:05
March 18 (Reuters) - Valneva SE VLS.PA: FY NET INCOME EUR -115.2 MILLION FY ADJUSTED EBITDA EUR -59.4 MILLION STRONG YEAR-END CASH POSITION OF EUR 109.7 MILLION FY TOTAL REVENUES OF EUR 174.7 MILLION FY CASH BURN EUR 52.9 MILLION IN 2025 2026 TO BE POTENTIALLY TRANSFORMATIONAL YEAR WITH PHASE 3 LYME DISEASE DATA EXPECTED IN H1 OUTLOOK 2026: TOTAL REVENUES TO RANGE BETWEEN EUR 155 MILLION AND 170 MILLION OUTLOOK 2026: PRODUCT SALES BETWEEN EUR 145-160 MILLION OUTLOOK 2026: OPERATING CASH BURN EXPECTED TO DECLINE FURTHER Source text: ID:nGNE8CwJsN Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency